Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
The Evolving Landscape of Systemic Therapies and Oncology Outcomes
share announcement

The Evolving Landscape of Systemic Therapies and Oncology Outcomes

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 7411

Special Issue Editors

Dr. Dominick Bosse

E-Mail Website
Guest Editor
Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Interests: chemotherapy; medical oncology; renal cell carcinoma; prostate cancer; transitional cell carcinoma; germ cell tumors; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals
Dr. Arif Awan

E-Mail
Guest Editor
School of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada
Interests: clinical trials; precision oncology; breast cancer and melanoma

Special Issue Information

Dear Colleagues,

Over the last decades, the armamentarium of systemic therapies against cancer has expanded to include immunotherapy and targeted therapies in addition to the traditional cytotoxic chemotherapies and endocrine therapies. These novel therapies have improved survival outcomes for selected patients and questioned whether surrogates of progression-free survival or response rates for overall survival are appropriate for patients treated with modalities.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:

  • Immunotherapy past, present and future: how it changed patient's survival and raise the need for new oncology endpoints.
  • The emergence of novel immunotherapies to overcome resistance and sensitize cold tumor to improve outcomes
  • Next generation sequencing and personalized medicine: How it transformed new drugs development and clinical trial research
  • Surrogate endpoints in the era of targeted therapy and immunotherapy
  • Epidemiologic perspective on the emergence of novel systemic therapies including impact on  clinical outcomes,  social cost and impacts on disparities within developed and across developing countries..

We look forward to receiving your contributions.

Dr. Dominik Bosse
Dr. Arif Awan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Immunotherapy
  • survival outcomes
  • next-generation sequencing
  • oncology
  • clinical trials
  • new drug development
  • epidemiology
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 427 KiB  
Article
DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
by Theodore J. Wigle, Samantha Medwid, Cameron Ross, Ute I. Schwarz and Richard B. Kim
Curr. Oncol. 2023, 30(1), 663-672; https://doi.org/10.3390/curroncol30010051 - 4 Jan 2023
Cited by 7 | Viewed by 3095
Abstract
Fluoropyrimidine chemotherapy is associated with interpatient variability in toxicity. A major contributor to unpredictable and severe toxicity relates to single nucleotide variation (SNV) in dihydropyrimidine dehydrogenase (DPYD), the rate-limiting fluoropyrimidine metabolizing enzyme. In addition to SNVs, a study of Finnish patients [...] Read more.
Fluoropyrimidine chemotherapy is associated with interpatient variability in toxicity. A major contributor to unpredictable and severe toxicity relates to single nucleotide variation (SNV) in dihydropyrimidine dehydrogenase (DPYD), the rate-limiting fluoropyrimidine metabolizing enzyme. In addition to SNVs, a study of Finnish patients suggested that a DPYD exon 4 deletion was observed in their population. To better understand the potential generalizability of such findings, we investigated the presence of this exon 4 deletion in our Canadian patient population, using a TaqMan assay. We selected 125 patients who experienced severe fluoropyrimidine-associated toxicity, and 125 matched controls. One patient in the severe toxicity group harbored a haploid DPYD exon 4 deletion, and required a 35% dose reduction after their first fluoropyrimidine treatment cycle due to toxicity and required an additional 30% dose reduction before tolerating treatment. The predicted allele frequency was 0.2% in our cohort, much lower than the 2.4% previously reported. We also carried out a literature review of copy number variation (CNV) in the DPYD gene, beyond fluoropyrimidine toxicity and show that various types of CNV in DPYD are present in the population. Taken together, our findings suggest that CNV in DPYD may be an underappreciated determinant of DPYD-mediated fluoropyrimidine toxicity. Full article
(This article belongs to the Special Issue The Evolving Landscape of Systemic Therapies and Oncology Outcomes)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 307 KiB  
Review
Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
by Alexius John, Lavinia Spain and Anis A. Hamid
Curr. Oncol. 2023, 30(1), 923-937; https://doi.org/10.3390/curroncol30010070 - 9 Jan 2023
Cited by 7 | Viewed by 3284
Abstract
Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes. To date, clinical trials evaluating the use of immunotherapies and targeted [...] Read more.
Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes. To date, clinical trials evaluating the use of immunotherapies and targeted therapies have predominantly been conducted in patients with clear cell histology. A comprehensive review of the literature has been undertaken in order to describe molecular pathogenic mechanisms pertaining to each nccRCC subtype, and concisely summarise findings from therapeutic trials conducted in the nccRCC space. Full article
(This article belongs to the Special Issue The Evolving Landscape of Systemic Therapies and Oncology Outcomes)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop